Osimertinib Tablets Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 40 mg, 80 mg
Reference Brands: Tagrisso® (US & EU)
Category: Oncology Cancer Care
Osimertinib Tablets is available in Oral Tablets and strengths such as 40 mg, 80 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Osimertinib Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Osimertinib Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Osimertinib Tablets are a third-generation tyrosine kinase inhibitor (TKI) used in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), including T790M resistance mutations. Marketed under the brand name Tagrisso®, Osimertinib selectively targets and inhibits EGFR mutations, providing a more precise treatment for metastatic NSCLC. Available in 40 mg and 80 mg tablet strengths, Osimertinib offers significant benefits in advanced lung cancer care. Manufactured under GMP-compliant conditions, it is an effective and reliable solution for US and EU pharmaceutical distributors looking to provide cutting-edge oncology treatments in precision medicine.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers